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Purpose. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is known to improve cardiorespiratory function and
outcome in neonates with severe respiratory failure. We tested the hypothesis that VA-ECMO therapy improves the microcircu-
lation in neonates with severe respiratory failure. Methods. This single-center prospective observational pilot study took place in
an intensive care unit of a level III university children’s hospital. Twenty-one-term neonates, who received VA-ECMO treatment,
were included. The microcirculation was assessed in the buccal mucosa, using Orthogonal Polarization Spectral imaging, within
24 hours before (T1) and within the first 24 hours after initiation of ECMO treatment (T2). Data were compared to data of a
ventilated control group (N = 7). Results. At baseline (T1), median functional capillary density (FCD), microvascular flow index
(MFI), and heterogeneity index (HI) did not differ between the ECMO group and the control group. At T2 the median FCD was
lower in the control group (median [range]: 2.4 [1.4–4.2] versus 4.3 [2.8–7.4] cm/cm2; P value <0.001). For MFI and HI there were
no differences at T2 between the two groups. Conclusion. The perfusion of the microcirculation does not change after initiation of
VA-ECMO treatment in neonates with severe respiratory failure.
1. Introduction
Extracorporeal membrane oxygenation (ECMO) is a cardio-
pulmonary bypass technique used as life support in selected
newborns and children with acute reversible cardiorespira-
tory failure when conventional management is not successful
[1, 2]. Worldwide, over 24,000 neonates have been treated
with ECMO for respiratory problems [1–3].
ECMO therapy gives time to restore normal pulmonary
oxygenation in neonates with severe respiratory failure who
do not respond to maximal conventional therapy and is
regarded as a bridge to recovery [1, 2, 4]. The institution
of venoarterial ECMO (VA-ECMO) partly takes over oxy-
genation, and carbon dioxide removal and thereby allows
ventilator settings to be reduced and restores circulation [4].
The institution of an ECMO circuit in neonates results
in an expansion of the circulating volume by approximately
factor 2.5. In VA-ECMO, the heart is bypassed and flow in the
systemic circulation is generatedmostly by the ECMOpump,
producing nonpulsatile flow. Especially during high ECMO
flow rate (120–200mL/kg/min), this results in disturbance
of the physiologic blood flow, which can be represented by
a flattening of the arterial pulse waves on invasive blood
pressure monitoring [4, 5].
In neonatal patients with severe respiratory failure, who
meet the criteria for ECMO treatment [4], the circulation
and oxygenation are severely compromised. Reflecting this
condition, these patients’ microcirculatory parameters are
significantly reduced before VA-ECMO [6]. At the time when
the patient no longer needs ECMO, the microcirculatory
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parameters are improved, correlating well with an improve-
ment in clinical condition [6]. After VA-ECMO initiation,
circulation and oxygenation generally improve rapidly and
patients show a decrease in the need for vasoactive medica-
tion. Direct effects of artificial, nonpulsatile ECMO flow on
the microcirculation are still not completely understood.
Based on clinical observations and the instant decrease
of need for vasoactive medication after the start of ECMO
therapy, we hypothesize that microcirculatory alterations
observed in neonates with severe respiratory failure improve
with the initiation of ECMO therapy.
2. Materials and Methods
2.1. Patients. Neonatal patients (aged ≤28 days) admitted
to our intensive care unit and treated with VA-ECMO were
enrolled in this study. Patients were treated with ECMO,
according to our unit specific policy. Patients suffering from
congenital heart disease were excluded.
In accordance with the guidelines of the medical ethical
review board of our hospital, informed consent was waived
when standard therapy is monitored by noninvasive tech-
niques.
Patients in the study group had severe cardiorespira-
tory failure and hypoxemia despite adequate conventional
treatments such as mechanical ventilation, sedation, muscle
paralysis, vasoactive drugs, and nitric oxide inhalation. All
patients met the established entry criteria for ECMO [4].
Starting ECMO treatment in a newborn implies a massive
increase of the circulating volume (the priming volume of
the used system is ±350mL, which is about 1.5 times the
circulating volume of a newborn baby). The ECMO system
was primed with a combination of Ringer’s lactate, packed
red blood cells and albumen. Bicarbonate and calcium were
added based on bloodgas analysis of the priming fluid.
Initially the aimed ECMO flow rate was 150–200mL/kg/min
and after 24 hours weaning of the flow was started under
guidance of changes in arterial pO2 and signs of pulmonary
hypertension.
In addition to the microvascular measurements, patient’s
demographic and clinical parameters, such as gender, birth
weight, gestational age, postnatal age, diagnosis, ECMO flow,
heart rate, blood pressure, mean arterial blood pressure,
body temperature, administered medication, hemoglobin,
and hematocrit levels were recorded. Data were compared
to data of control subjects, with severe respiratory failure,
who did not receive ECMO treatment. In the control
group, patients were measured several consecutive days after
admission. The first two measurements on consecutive days
were taken to serve as control for T1 and T2 and to evaluate
the changes without ECMO treatment.
2.2. Procedures. The microcirculation was assessed within 24
hours before start of ECMO (T1) and within 24 hours after
start of ECMO (T2). OPS imaging [7] was used to visualize
the microvascular network of the buccal mucosa. The mea-
surements were done with a CYTOSCAN E-II Backfocus-
type device (Cytometrics, Philadelphia, PA, USA), using the
5x objective.
Before the measurements, saliva was gently removed with
gauze. The lens of the OPS-imaging device was covered with
a disposable sterile cap and was applied to the buccal mucosa
without pressure, as described before [6]. Images from 3
different regions were obtained and stored on digital video-
tapes, using a Sony DSR-20P digital video recorder. Segments
of 5 seconds were selected and captured in AVI (audio video
interleave) format. Video segments that did not meet quality
criteria were discarded [6, 8]. For every measurement, the
functional capillary density (FCD), microvascular flow index
(MFI), and heterogeneity index (HI) of the different video
segments were averaged. If only one segment met the quality
criteria, this score was taken. (This was the case for 2 ECMO
patients at T2 and 1 control patient at T1).
2.3. Microcirculatory Analysis. Quantification of the images
was performed as described previously [6, 7]. To investigate
vessel density, the images were analyzed with the Capiscope
software program (version 3.7.1.0, KK Technology 1993–
2000). For the FCD calculation, the analyst is required to
trace out the path of the moving red blood cells within the
capillaries (vessels, smaller than 10 µm). A functional capil-
lary is defined as a capillary that has at least one red blood cell
moving through it, during the observation period. Dividing
the length of the perfused capillaries by the area gives the
functional capillary density value expressed in cm/cm2.
The flow pattern was studied using the MFI, and the
HI [8]. For MFI the predominant type of flow for small,
medium, and large vessels in every quadrant of the images
was determined, as described before by Boerma et al. [9].
For every measurement, the scores for the different video
segments were averaged. If only one segment met the quality
criteria, this score was taken. HI was calculated as the highest
site flow velocity minus the lowest site flow velocity, divided
by the mean flow velocity of all sites per measurement [8].
2.4. Statistical Analysis. The data were analyzed using SPSS
17.0. Continuous data are presented as median and range,
discrete data as number and percentage. The intergroup
differences at T1 were assessed using the MannWhitney test.
Changes over time were assessed using analysis of covariance
(ANCOVA) with the T2 measurement as outcome variable,
the groups as factor, and the T1 measurement as covariate.
In this way, differences at T2 are corrected for the baseline
measurements. The level of significance was set at P < 0.05.
3. Results
During the study period, 31 VA-ECMO patients were eligible
for inclusion. Twenty-one patients were included in the
study. Four patients were missed for inclusion due to logistic
reasons (a researcher was not contacted in time or no
investigator or camera available). Six patients were excluded
because their video segments did notmeet the quality criteria
[6]. The excluded ECMO patients did not differ from the
included ECMO patient group for gestational age, postnatal
age, diagnosis, duration of ECMO treatment, or mortality.
In the control group, four patients were missed for inclusion
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Table 1: Demographic data.
ECMO N = 21 Controls N = 7
Gestational age [weeks] 39.0 (34.4–42.5) 38.1 (38.0–39.3)
Birth weight [kilograms] 3.1 (2.3–5.1) 3.0 (3.0–3.8)
Gender [males] (%) 12 (57) 4 (57)
Diagnosis [n] (%) CDH 10 (48) 7 (100)
MAS 5 (24)
PPHN 5 (24)
CCAM 1 (5)
Survival [n] (%) 18 (86) 7 (100)
Continuous data are presented as medians and range, discrete data as number and percentage. CDH: congenital diaphragmatic hernia, MAS: meconium
aspiration syndrome, PPHN: persistent pulmonary hypertension of the neonate, CCAM: congenital cystic adenomatoid malformation.
and seven patients had to be excluded due to insufficient
quality of the images. Demographic data are presented in
Table 1, clinical data in Table 2, and microcirculatory data
obtained by SDF are presented in Table 3.
At baseline (T1), median FCD did not differ between
the ECMO group and the control group (median [range]:
4.5 [2.4–7.7] versus 5.0 [1.8–7.2] cm/cm2, P value = 0.811)
(Figure 1). ANCOVA analysis indicated that at T2 themedian
FCD was 1.9 cm/cm2 lower in the control group than it was
in the ECMO group (median [range]: 2.4 [1.4–4.2] versus 4.3
[2.8–7.4] cm/cm2; P value <0.001). For MFI and HI, there
was neither a difference at T1 nor a difference at T2 between
the two groups (see Table 3 for absolute MFI values and HI
values per vessel type as well as the associated P values).
At baseline, the disease severity indices oxygenation index
(median [range]: 31 [5–94] versus 5 [3–13]; P value = 0.004)
and the PELOD score (median [range]: 20 [11–31] versus 11
[11–20]; P value = 0.006) were more unfavourable for the
ECMO patients than for the control patients. The heart rate
was higher in the ECMOpatients (median [range]: 180 [120–
220] versus 138 [113–191] bpm; P value = 0.046), whereas
the mean arterial blood pressure and the pulse pressure did
not differ. The need for vasoactive medication as indicated by
the vasopressor score did not differ between the two groups
at T1. Mean airway pressure (median [range]: 18 [12–27]
versus 14 [9–16] cm H2O; P value = 0.019) and the median
dosage of inhaled nitric oxide (median [range]: 20 [0–40]
versus 0 [0–19] ppm; P value = 0.012) were both higher in
the ECMO patients than in the control patients.
At T2, ANCOVA analysis indicated that there was no
difference in OI between the ECMO group and the control
group. The heart rate and the mean arterial blood pressure
did not differ. Pulse pressure was lower in the ECMOpatients
than in the control patients (median [range]: 10 [0–33]
versus 24 [15–32]; P value <0.001). The vasopressor score
did not differ at T2, nor did the mean airway pressure.
Regarding the dosage of inhaled nitric oxide, ANCOVA
analysis indicated that the need for more inhaled nitric oxide
in the ECMO patients at T1 had disappeared at T2.
All patients in the control group survived. Three patients
in the ECMO-treated group (2 diagnosed with CDH, 1
with CCAM) did not survive, due to recurrent and therapy-
resistant pulmonary hypertension. Subanalysis showed that
neither FCD nor MFI, nor HI differed between the ECMO
survivors and the ECMO nonsurvivors at T1 and at T2.
4. Discussion
The main finding of this study was that there was no change
in microcirculatory parameters after the start of VA-ECMO
therapy in patients with severe respiratory failure. In both
the ECMO and the control group, the FCD at T1 was
significantly lower than FCD values of neonates without
any respiratory or cardiovascular problems (who served as
a control group in a previous study [6]). The FCD in those
patients was 8.1 cm/cm2 (range, 6.6–9.4). MFI values in both
study groups were relatively high and HI values relatively
low, in contrast to observations in patients with sepsis. There
was no difference in MFI and HI between the two groups
at T1 and T2. Deterioration of the FCD was observed in
patients with severe respiratory failure, who did not receive
ECMO treatment. Despite the fact that patients in the ECMO
group were more severely ill, in comparison to the patients
in the ventilated control group (Oxygenation Index and
PELOD score in ECMO group significantly higher), ECMO
succeeded to better microcirculatory support compared to
solely conservative treatment with mechanical ventilation
and pharmacologic support.
Thus, ECMO seems to prevent a further deterioration
of microcirculatory perfusion. The start of ECMO instigates
an instant improvement in oxygenation, which makes vaso-
pressors and the use of high mean airway pressures instantly
redundant. No correlation between the vasopressor score or
the main airway pressure and FCD was found.
Deterioration of microvascular perfusion in patients in
the ventilated control group was not correlated with mor-
tality. This is in contrast with observations in patients with
severe sepsis [10–12]. The underlying pathophysiology in
patients in our study is different from sepsis. Therefore,
data from patients with sepsis cannot be extrapolated to
this patient group. Both patient groups revealed a relatively
normal flow pattern and selectively affected vessel density.
At this stage, it is not clear if this could be explained by
their specific hemodynamic pattern. Patients in this study
suffered from hypoxic respiratory failure, mainly due to
failure of adequate feto-neonatal transition of the circulation.
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Table 3: Microcirculatory values.
T1 ECMO T2 ECMO T1 Controls T2 Controls P value at baseline∗ P value over time†
N = 21 N = 21 N = 7 N = 7
FCD [cm/cm2] 4.5 (2.4–7.7) 4.3 (2.8–7.4) 5.0 (1.8–7.2) 2.4 (1.4–4.2) 0.811 <0.001
MFI Large 2.76 (2.50–3.00) 2.88 (2.34–3.00) 2.92 (2.50–3.00) 3.00 (2.63–3.00) 0.266 0.367
MFI Medium 2.67 (2.13–3.00) 2.75 (2.13–3.00) 2.75 (2.38–3.00) 2.81 (2.50–3.00) 0.254 0.411
MFI Small 2.75 (2.06–3.00) 2.75 (2.08–3.00) 2.88 (2.44–3.00) 2.90 (2.63–3.00) 0.574 0.090
HI Large 0.10 (0.00–0.30) 0.09 (0.00–0.40) 0.09 (0.00–0.29) 0.00 (0.00–0.26) 0.951 0.2406
HI Medium 0.14 (0.00–0.60) 0.11 (0.00–0.35) 0.10 (0.00–0.51) 0.00 (0.00–0.27) 0.736 0.2421
HI Small 0.18 (0.00–0.73) 0.09 (0.00–0.37) 0.09 (0.00–0.40) 0.00 (0.00–0.17) 0.579 0.0971
Data are presented as median and range.
∗Intergroup differences at T1 were assessed using Mann-Whitney test. †For the time-dependent variables, differences at T2 were assessed using ANCOVA
with the baseline measurement as covariate.
FCD: functional capillary density, MFI: microvascular flow index, HI: heterogeneity index.
P < 0.001
T1 T2
(a) (b)
T1 T2
10
9
8
7
6
5
4
3
2
1
0
ECMO patients Control patients
FC
D
 (
cm
/c
m
2
)
Figure 1: Diagram showing the functional capillary density (FCD). (a): ECMO patients, (b): ventilated control patients. No difference in
median FCD was seen at T1 between the two groups: 4.5 cm/cm2 (range 2.4–7.7) versus 5.0 cm/cm2 (range 1.8–7.2), P value = 0.811. At T2,
FCD was higher in ECMO group than in the control group: 4.3 cm/cm2 (range 2.8–7.7) versus 2.4 cm/cm2 (range 1.4–4.2), P value <0.001.
Typically, these patients display a hemodynamic pattern
with persistent pulmonary hypertension of the neonate
(PPHN), which is clinically characterized by a persistent high
pulmonary vascular resistance and an abnormal vascular
response, leading to worsening of gas exchange and shunting
(intracardiac, extracardial, and intrapulmonary) and right
ventricular failure. PPHN occurs as a primary disease or in
association with abnormal lung development, for example,
in congenital diaphragmatic hernia and is a critical determi-
nant of morbidity and mortality [13].
All patients had pulmonary hypertension, assessed by
echocardiography and differences in the pre- and postductal
oxygen saturation (due to shunting through persistent fetal
pathways such as the ductus arteriosus). This can compro-
mise the pulmonary venous return and preload of the left
ventricle and, therefore, influence global hemodynamics. No
measures of cardiac output (CO) were available in this study,
so this cannot be verified.
During cardiopulmonary bypass (CPB) in adults, micro-
circulatory alterations have been described before [14–17].
We found one report on microcirculatory alterations during
CPB in neonates where OPS was used, which shows a
reduction in vessel density during CPB [18].
The circulatory volume increases by about 150%, when
a newborn is attached to an ECMO circuit. Therefore, it is
necessary that the system is primed with blood products.
The addition of these products is titrated against normal
values for the age. Thus, with ECMO, blood is transfused,
which could improve the microcirculation [19]. However,
there was no increment in the hemoglobin level, to support
this. With the attachment of the system, a large amount of
fluid is administered, which could influence the perfusion of
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the microcirculation [20]. Due to the relatively large amount
of circulating volume in the system, it is difficult to comment
on volume expansion in the patient in absolute numbers.
During cannulation and shortly afterwards extra fluid was
administered on discretion of the treating physician, based
on clinical judgment and following standard unit policies
and procedures.
Disturbance of physiologic flow also triggers the cate-
cholamine system leading to vasoconstriction and altered
tissue perfusion [21]. Although themechanism behind this is
not completely understood, Agati et al. [22–24] reported that
in cardiac patients on CPB nonpulsatile flow seemed to affect
the microcirculation and organ perfusion in a more negative
way than pulsatile flow did. No correlation between ECMO
flow and FCD was seen in our study.
All in all, the initiation of ECMO therapy instigates many
changes in the homeostasis of the critically ill patient. It is
difficult to unravel the complex processes that take place and
to assess separate factors, in order to understand the effect
of the different components of the treatment. Nowadays, the
importance of microcirculatory improvement is recognized
[25, 26]. With this paper, we have shown that the current way
of using ECMO treatment stabilizes the microcirculation,
but does not restore microvascular density. More research is
needed to explore the different factors that have influence on
the microcirculation. In addition, follow-up investigations of
the microcirculation are necessary as well as comparison of
survivors and nonsurvivors within the group that received
ECMO treatment. In this way, the prognostic value of
microcirculatory parameters can be determined.
There were some limitations to our study. First, the lack
of COmeasurements limits the possibility to relate microvas-
cular observations to global hemodynamics. Changes in CO
could possibly play a role in the decrease of FCD between
T1 and T2 in the control group. In children, mixed venous
saturation and cardiac output are not routinely measured.
A prerequisite for adequate CO monitoring is a tool that
is accurate, is easy to use, and has an acceptable risk-
benefit profile. These three factors have constituted themajor
hurdle to bedside pediatric cardiac output measurement to
date [27]. The reliability of echocardiography evaluation of
cardiac output in children is debatable because even in the
hands of experienced operators the inter- and intraindividual
variation is large [28].
Second, the control group consisted entirely of patients
with CDH, while the ECMO group also contained patients
with severe respiratory failure and pulmonary hypertension
due to other causes. Patients with CDH suffer from a specific
hemodynamic pattern, based on a structural congenital
abnormality [13]. This could possibly have different implica-
tions on the development of global hemodynamics and the
microcirculation.
Unfortunately, the exact amounts of priming fluids and
fluids, given during or shortly after the cannulation pro-
cedure prior to T2, are not well documented. In addition,
12 of the 21 ECMO patients were first measured within 2
hours of IC admission. In these patients, no reliable data on
the amount of fluid administration prior to admission was
available. Therefore, we are unable to provide reliable data for
fluid balance, fluid amount, and type of fluids administered
for ECMO patients in this study.
In this pilot study, the microcirculation was assessed
before and after the start of ECMO; therefore, long-term
effects of ECMO could not be evaluated. In addition, the
median time interval for the subsequent SDF measurements
in the ECMO group was shorter than that of the control
group. The earlier microcirculatory evaluation in the ECMO
group might be of influence on our results.
Finally, this study is observational and not randomized
controlled, which skews outcome data. If children in the
control group had disposed progressive respiratory and/or
circulatory failure, they would have received ECMO treat-
ment. From an ethical perspective, randomization for this
type of treatments is unacceptable.
5. Conclusion
The perfusion of the microcirculation does not change after
initiation of VA-ECMO treatment in neonates with severe
respiratory failure.
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